In addition, patients with HER2-positive breast cancer who started adjuvant therapy with trastuzumab at 31–60 days after surgery showed no significant differences in OS, RFS, and DRFS compared with patients who started adjuvant therapy at ≤30 days after surgery. This evidence concerns the gene ERBB2 and breast cancer.